Sarepta Therapeutics (SRPT) Stock Hits One-Year Low Today After Eteplirsen Update

Posted: Published on January 13th, 2015

This post was added by Dr Simmons

NEW YORK (TheStreet) -- Shares ofSarepta Therapeutics (SRPT) plunged more than 18% to a 52-week low of $11.33 on Monday after the biopharmaceutical company provided a 168-week update on its study of eteplirsen, the company's Duchenne muscular dystrophy (DMD) treatment.

Sarepta's update revealed thatanaccelerated decline in walking ability in the 168th week compared to the previous update after week 144. All the DMD patients lost some walking ability in the trial.

However, the update also revealed some encouraging news, as patients in the trialcontinue to walk more than three years after starting eteplirsen treatment. The patients showed no significant side effects or tolerability problems. Eteplirsen also seemed to slow the progression of DMD in the patients.

Must Read:Sarepta Updates Eteplirsen Study Results, FDA Filing Still on for Mid Year

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Jim Cramer's protg, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Read the original here:
Sarepta Therapeutics (SRPT) Stock Hits One-Year Low Today After Eteplirsen Update

Related Posts
This entry was posted in Muscular Dystrophy Treatment. Bookmark the permalink.

Comments are closed.